Timothy Eugene Sullivan - 28 Jan 2026 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Financial Officer
Signature
/s/ David Watson, attorney-in-fact for Timothy Sullivan
Issuer symbol
APLS
Transactions as of
28 Jan 2026
Net transactions value
$0
Form type
4
Filing time
30 Jan 2026, 16:07:47 UTC
Previous filing
23 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sullivan Timothy Eugene Chief Financial Officer C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM /s/ David Watson, attorney-in-fact for Timothy Sullivan 30 Jan 2026 0001707000

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Award $0 +58,140 +62% $0.000000 152,041 28 Jan 2026 Direct F1
holding APLS Common Stock 60,396 28 Jan 2026 The Timothy E Sullivan Irrevocable Trust of 2023 F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents a Restricted Stock Unit award granted on January 28, 2026 that vest 25% annually over four years from grant date subject to continued service.
F2 The securities are held by The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.